Aakaar Medical Technologies Limited IPO
Incorporated in 2013 under the leadership of Mr. Dilip Meswani—an industry veteran with over 25 years of experience in the aesthetics sector—Aakaar Medical Technologies Private Limited is a leading player in India’s medical aesthetics and cosmetic devices market. Mr. Meswani began his journey in 1999 through a proprietary venture and later consolidated operations under Aakaar, scaling it into a professionally managed private limited company.
Business Model & Operations
Aakaar operates a pure B2B (Business-to-Business) model, catering primarily to dermatologists, aesthetic physicians, and plastic surgeons across India. These professionals either use Aakaar’s products in clinical treatments or retail them to end consumers. The company has built a robust portfolio that includes both own brands and imported brands, covering a wide spectrum of aesthetic solutions—from skincare and haircare to injectables and high-tech aesthetic devices.
Revenue Mix (FY25)
a) Imported Brands: 62.28%
Products are sourced from international partners (South Korea, Spain, Italy, Austria) and sold under exclusive distribution arrangements.
b) Own Brands: 37.72%
Products are manufactured domestically either through:
– White labelling (with Aakaar as the marketing agency), or
– Loan licensing (with Aakaar as both manufacturer and marketer).
Product Portfolio
a) Own Brands
i) Swyada – Skin moisturizers, gels, masks, and medi-facial kits
ii) Tubelite – Injectables, cleansers, sunscreens, and haircare solutions
iii) Etrelume, Etreluxe, Exoluxe, Etreclaire – Advanced skincare and mesotherapy products
iv) Etrehair, Balback – Hair serums and nutraceuticals
v) Lytec, DRS1512 – Skin lightening and post-procedure products
vi)Femichair, Synergy+, Magnus – Aesthetic devices for urinary incontinence, hydra-facial, tattoo removal, and pigmentation treatment
b) Imported Brands
1. AQULIFT, Saypha (Croma), Tesslift – Injectable threads, dermal fillers, and anti-aging solutions
2. Theraderm, Innoaesthetics, Meline – Serums, depigmentation products, and sunscreens
3. Platina, Xelix, Regenera – Laser hair reduction and hair transplant devices
4. Siax (Medytox), Brand 1 – Purified botulinum toxin and scar treatment
5. Tinefcon – Skin treatment products, including solutions for psoriasis
Strategic Focus
Aakaar’s strategic differentiation lies in its exclusive B2B distribution model, depth in product variety, and partnerships with globally reputed aesthetic brands. Its dual approach of importing international bestsellers and launching in-house brands using cost-effective Indian manufacturing provides both margin advantage and product depth.
Future Outlook
With a clear focus on expanding its aesthetic product pipeline, leveraging its pan-India dermatologist and clinic network, and launching new-age, clinically effective formulations, Aakaar Medical Technologies is well-positioned to tap into the growing demand for professional aesthetic solutions in India.
Objects of the Aakaar Medical Technologies Limited IPO:
Aakaar Medical Technologies Limited IPO Details:
Open Date: | Jun 20 2025 |
Close Date: | Jun 24 2025 |
Total Shares: | 37,50,400 |
Face Value: | ₹ 10 Per Equity Share |
Issue Type: | book Building |
Issue Size: | 27 Cr. |
Lot Size: | 1600 Shares |
Issue Price: | ₹ 68-72 Per Equity Share |
Listing At: | NSE Emerge |
Promoters And Management:
Financials of Aakaar Medical Technologies Limited IPO:
Particulars (In lakh) | March-2025 | March-2024 | March-2023 |
Revenue from Operations | 6,158 | 4,611 | 3,278 |
EBITDA | 974 | 500 | 353 |
EBITDA Margin (%) | 15.81 | 10.84 | 10.76 |
PAT | 604 | 287 | 215 |
PAT Margin (%) | 9.81 | 6.22 | 6.57 |
Net Worth | 2,320 | 1,253 | 966 |
Return on Net Worth (%) | 33.81 | 25.88 | 24.35 |
RoCE | 21.02 | 17.68 | 22.3 |
Revenue from own brands | 2,311 | 1,394 | 774 |
Comparison With Peers:
Lead Manager of Aakaar Medical Technologies Limited IPO:
Registrar of Aakaar Medical Technologies Limited IPO:
Discussion on Aakaar Medical Technologies Limited IPO:
Leave a Reply
You must be logged in to post a comment.